EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Remarkable response to pazopanib plus vivolumab in a patient with pericardial synovial sarcoma carrying a novel genotype BRCA2 c. 968dupT: A case report

Xing Zhang, Qinqin Xu, Yongchang Zhang iD

Thoracic Cancer · 2024

DOI: 10.1111/1759-7714.15237 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Xing Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China. Hauptthemen laut MEDLINE: Sarcoma, Synovial, Mediastinal Neoplasms, Thymus Neoplasms, Heart Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pericardial synovial sarcomas (PSS) have a low incidence rate and are highly invasive with a dismal prognosis. Standard treatment includes surgery, radiotherapy and chemotherapy but with limited response. Here, we report the case of a 15‐year‐old nonsmoking youngster diagnosed with PSS who developed disease relapsed from surgery after 1 month. Next‐generation sequencing (NGS) using baseline tissue was performed, and BRCA2 c.968dupT was detected. Then pazopanib (a multitargeted inhibitor) plus nivolumab (an immune checkpoint inhibitor) was administered, with a partial response and progression‐free survival of 14 months. BRCA2 c.968dupT has not previously been reported in PSS and its response to targeted combination immunotherapy are not well characterized. Here, we report the efficacy of pazopanib combined with nivolumab in a PSS patient harboring BRCA2 c.968dupT and also provide the clinical evidence of the utility of NGS in exploring actionable mutations for solid tumor. Combination therapy based on immunotherapy may be a potential treatment choice for PSS harboring BRCA2 mutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sarcoma, SynovialMediastinal NeoplasmsThymus NeoplasmsHeart NeoplasmsPleural NeoplasmsIndazolesHumansAdolescentNivolumabPyrimidinesSulfonamidesBRCA2 Protein

Stichwörter der Autor:innen

BRCA2immunotherapypericardial synovial sarcomas (PSS)tyrosine kinase inhibitor (TKI)

Substanzen

NivolumabpazopanibPyrimidinesSulfonamidesBRCA2 protein, humanBRCA2 ProteinIndazoles

Autor:innen und Institutionen

  • Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
  • Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Department of Medical Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, Hunan, China.
  • Department of Medical Oncology, Qinghai Provincial People's Hospital, Xining, Qinghai, China.

ORCID-Profile: Yongchang Zhang

Förderung

  • Natural Science Foundation of Hunan Province

Zitieren

APA

Zhang, X., Xu, Q., & Zhang, Y. (2024). Remarkable response to pazopanib plus vivolumab in a patient with pericardial synovial sarcoma carrying a novel genotype BRCA2 c. 968dupT: A case report. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15237

Vancouver

Zhang X, Xu Q, Zhang Y. Remarkable response to pazopanib plus vivolumab in a patient with pericardial synovial sarcoma carrying a novel genotype BRCA2 c. 968dupT: A case report. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15237

BibTeX
@article{Zhang2024,
  author = {Zhang, Xing and Xu, Qinqin and Zhang, Yongchang},
  title = {Remarkable response to pazopanib plus vivolumab in a patient with pericardial synovial sarcoma carrying a novel genotype BRCA2 c. 968dupT: A case report},
  journal = {Thoracic Cancer},
  year = {2024},
  doi = {10.1111/1759-7714.15237}
}
Kostenlos starten →